Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
https://vaping360.com/vape-news/71584/juul-goes-after-competitors-with-patent-complaint/
The devices named in the complaint are:
Bo One
Bo+
Eonsmoke Device
Eonsmoke v2.0 Device
Eonsmoke Pods Pack
4X Pods Pack
Ziip Starter Kit
Plus Pods Pack
Xfire Device Kit
Xfire Pods Kit
Flair Xtreme Starter Kit
Myle Starter Kit
Pulse Starter Kit
3X Pods Pack
NO MENTION OF SFIO
SFIO patent worth at least hundreds of million
whats the float
This Patent covers thirty-four European countries
LAS VEGAS, NV--(Marketwire - April 5, 2011) - Smokefree Innotec, Inc. (PINKSHEETS: SFIO) an established international distributor of e-cigarettes, (http://www.sfio.us or http://www.realsmokefree.com) announced today through its President and CEO Thomas Schroepfer, that The company has been informed that its European Patent application has been granted for "SMOKING DEVICE, CHARGING MEANS AND METHOD OF USING IT" (Application No. 08 738 110.9 - 2313). In a correspondence recently received from the Company's patent attorneys, relaying a communication from the European Patent Office Examining Division: "The mention of the grant of the patent shall be published in the European Patent Bulletin as soon as possible after the requirements concerning the translation of the claims and the payment of the fees for grant and publishing, claims fees, designation fee and renewal fees as laid down in Rule 71 (3), (4), (6) and (8) and (9) EPC are fulfilled." The Company's patent attorneys have also informed SFI that the fees have been paid, and the patent is granted but will take 4 to 8 weeks for publication. This Patent covers thirty-four European countries.
Smokefree Innotec Obtains European Patent for Its Unique Smokeless and Vaporless E-Cigarette Design
LAS VEGAS, NV--(Marketwire - April 5, 2011) - Smokefree Innotec, Inc. (PINKSHEETS: SFIO) an established international distributor of e-cigarettes, (http://www.sfio.us or http://www.realsmokefree.com) announced today through its President and CEO Thomas Schroepfer, that The company has been informed that its European Patent application has been granted for "SMOKING DEVICE, CHARGING MEANS AND METHOD OF USING IT" (Application No. 08 738 110.9 - 2313). In a correspondence recently received from the Company's patent attorneys, relaying a communication from the European Patent Office Examining Division: "The mention of the grant of the patent shall be published in the European Patent Bulletin as soon as possible after the requirements concerning the translation of the claims and the payment of the fees for grant and publishing, claims fees, designation fee and renewal fees as laid down in Rule 71 (3), (4), (6) and (8) and (9) EPC are fulfilled." The Company's patent attorneys have also informed SFI that the fees have been paid, and the patent is granted but will take 4 to 8 weeks for publication. This Patent covers thirty-four European countries.
Mr. Schroepfer further stated, "After a great deal of expenditure in time and funding, the companies vapor less e-cigarette REAL product line is in final production stages of perfecting prototypes for testing and evaluation, with a release to the market expected within weeks. The product line will be prominently featured on the company's web site and available for sale in its shopping cart."
About Smokefree Innotec, Inc. (www.smokefree-innotec.com): Smokefree Innotec, Inc. is in the business of designing, developing, manufacturing and marketing hi-tech, nicotine and non-nicotine cigarette-like delivery devices which are completely smoke and vapor-free and tobacco-free. Smokefree Innotec's products are designed to protect the non-smoker from second hand smoke and all its effects while providing the smoker a way to enjoy a smoke-free cigarette anywhere, including places where vapor emissions or smoking tobacco or similar substances is prohibited. Further, our products will allow the smoker to enjoy smoking either nicotine or flavored non-nicotine cigarettes while not having to worry about the offensive dangers and ill effects of regular cigarette smoking. However Smokefree Innotec products are not intended for any prevention or therapeutic treatment of any disease.
http://www.marketwired.com/press-release/smokefree-innotec-retains-swiss-patent-attorneys-extend-its-international-patent-coverage-1178543.htm
international patent too
Smokefree Innotec Retains Swiss Patent Attorneys to Extend Its International Patent Coverage
NASHVILLE, TN--(Marketwire - December 3, 2009) - Smokefree Innotec, Inc. (PINKSHEETS: SFIO) (http://www.sfio.us or http://www.smokefree-innotec.com) announced today that its Swiss patent and trademark attorneys Spierenburg & Partners AG have started nationalizing and regionalizing the PCT patent application for SFIO's Real Smokefree product.
The first countries where Spierenburg & Partners foreign associates have entered into the national phase are Australia, Brazil, Canada, China, Japan, South Korea, South Africa, Europe, Russia and the United States.
SFIO President Thomas Schroepfer commented: "We are right on track with distribution deals around the globe and the rapidly increasing interest in our product proves that we have a very valuable piece of intellectual property to protect. We are happy to retain the expertise of Pieter Spierenburg's firm and the timing of the Patent procedures seems perfect."
About Smokefree Innotec, Inc.:
Smokefree Innotec, Inc. is in the business of designing, developing, manufacturing and marketing a Hi-Tech, smokeless cigarette innovation. Real Smokefree is a Patent Pending, odorless, cigarette-style electronic device and is designed to protect the non-smoker from second hand smoke and all its effects, while providing the smoker a way to enjoy a smoke-free cigarette anywhere, including places where smoking is prohibited. Further, our products will allow the smoker to enjoy smoking while not having to worry about the dangers and ill effects of regular cigarette smoking.
its all about the value of the patent IMO
JUUL $13BILLION or more
SFIO $9M
https://www.cspdailynews.com/tobacco/oregon-stops-sale-unapproved-e-cigarettes
Separately, Smokefree Innotec Inc. recently issued a statement referring to articles in USA Today and The New York Times regarding the FDA taking aim at e-cigarettes. The national newspapers stated that tests show that certain e-cigarettes contain "known carcinogens and toxic chemicals," including diethylene-glycol (an ingredient used in antifreeze, printing ink, brake fluid and glue) and nitrosamine (which is used in rubber products, the tobacco industry and, less concentrated, in beer and fish products).
Thomas Schroepfer, president of Smokefree Innotec, said, "The company's electronic cigarette was not among those tested and is completely different from those tested as we do not use any kind of transponder substance. We have received confirmations from industry sources with knowledge of our product design and manufacturing process that no carcinogens or toxic chemicals capable of polluting our product are used in the manufacturing process and that the design of our product ensures a lower consumption level of nicotine, while still providing satisfaction to the consumer."
Fresh off a $1.8 billion investment in Canadian cannabis company Cronos Group (CRON), Altria on Thursday purchased a 35% stake in e-cigarette maker Juul, worth $12.8 billion. The Wall Street Journal was the first to report that Altria (MO) was considering an investment.
damn... i could have bought more earlier below 0.005
no smoking
no vaping...
smokefree
http://www.nbcnews.com/id/39149263/ns/business-press_releases/t/cannabis-science-smokefree-jv-llc-domestic-limited-liability-company-created-has-started-testing-enter-potential-multi-billion-medical-cannabis-market-smokefree-innotec-cannabis-science-jv/#.XDOq0VxKiUl
so there is thie JV: CANNABIS SCIENCE SMOKEFREE JV LLC
https://www.businesswire.com/news/home/20100818006462/en/Smokefree-Innotec-Confirms-Joint-Venture-Cannabis-Science
CBIS is 100M company
SFIO is now 3M
smokefree marijuana... maybe
ALQA
remember IGCC
from 20/30 cents to 14 dollars and it has more OS
Share Statistics
Avg Vol (3 month) 3 4.69M
Avg Vol (10 day) 3 337.71k
Shares Outstanding 5 7.17M
Float 67.74k
just bought this stock
What is GCANRx's O/S and Float?-
As of October 26, 2018 the outstanding shares are 30,846,492 and the float is approximately 13,426,759
The Greater Cannabis Company skyrocketed on a high turnover of traded shares on announcing a breakthrough of its licensed technology EPP. The company has confirmed completion of development and reformulation of the eluting patch EPP technology.
The eluting patch was developed for pharmaceuticals as well as for over the counter products and other oral health applications. The company has already completed all the necessary testing of formulations in preparation of the commercial launch of its products. The technology has already proved to have the ability to afford consumers a safe alternative to other cannabinoid delivery systems.
Commercialization Drive
Buoyed by the results of the tests so far and the potential of the EPP technology, The Greater Cannabis Company has started ramping up efforts to commercialize the technology. The company is eying sublicenses as well as joint venture agreements. Target partners include licensed cannabis producers in the U.S Canada as well as abroad.
The Greater Cannabis Companies is also eyeing deals with pharmaceutical companies planning to leverage cannabinoid therapies. The sole focus is bringing the technology to market through collaborations that have the potential to generate long-term value.
“Our shareholders should know that our attention is being placed where it should be, on building long-term shareholder value by growing the business and generating revenues. Our objective is to achieve business success, and as such we have no intention of being distracted by day to day stock price, or message boards,” said CEO Mr. Aitan Saccharin, CEO of Greater Cannabis.
Euro Tech Holdings Says A Presentation By Its Sister Co. PACT 'caught attention of regional marine service companies and trading companies who are interested in working with us as business partners.'
11:47 am ET November 6, 2018 (Benzinga) Print
http://www.euro-tech.com/en/euro_news_detail.asp?news_id=124
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
bought todaY
Does IGCC keep the cash they have accummulated
there were supposed to be 550 patients on last trial
they achieved 50% around April
then they randomly selected 50 which had the failed results last August.
Based on this results, they could stop the trial which they did or re-analyze data which they did
they said it worked in 4 weeks even with PTSD of more than 9 years.
but it didnt work for 12 weeks with PTSD of more than 9 years
now the new trial will only involve with PTSD 9 years or less
and results will be announced after 4 weeks
what am i missing here
this should be 4 dollars by now
the drug works if the PTSD happened 9 years or less...
that is the new target plus the civilian trauma
they also said 4 weeks results then 12 weeks.
it already worked in 4 weeks before...
they might need financing,, but it doesnt matter if around spring 2019, they announce that it works
accummulate
TNX-102 SL, as a bedtime treatment for agitation in Alzheimer’s disease, received Investigational New Drug (IND) clearance in May 2018. Fast Track designation was granted by the FDA in July. Fast track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. It reflects the recognition by the FDA that TNX-102 SL has the potential to address a large unmet medical need for a serious condition. A Phase 2, potential pivotal, efficacy study protocol submitted in July 2018 is pending FDA review and acceptance.
IN APRIL 2018
vTv Therapeutics Announces Topline Results from the First STEADFAST Phase 3 Study Evaluating Azeliragon in People with Mild Alzheimer’s Disease
HIGH POINT, N.C.--(BUSINESS WIRE)--Apr. 9, 2018-- vTv Therapeutics, Inc. (vTv) (Nasdaq:VTVT) today announced that results from Part A of the Company’s Phase 3 STEADFAST study of the investigational medication azeliragon in people with mild Alzheimer’s disease did not meet either co-primary efficacy endpoint. Patients taking azeliragon compared with placebo did not improve in cognitive or functional outcomes as measured by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and the Clinical Dementia Rating Scale Sum of Boxes (CDR-sb).
IN JUNE 2018
View printer-friendly version
<< Back
vTv Therapeutics Announces Topline Results from Part B of Phase 3 STEADFAST Study
HIGH POINT, N.C.--(BUSINESS WIRE)--Jun. 12, 2018-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that results from Part B of the Company’s STEADFAST Study of the investigational medication azeliragon in people with mild Alzheimer’s disease did not meet co-primary efficacy endpoints. The prespecified subgroup consisted of azeliragon-treated patients with maximal azeliragon plasma concentrations of less than 7.5 ng/mL and baseline Mini Mental State Examination (MMSE) scores between 19 and 27, and the endpoints were statistically significant improvement in cognitive or functional outcomes as measured by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and Clinical Dementia Rating Scale Sum of Boxes (CDR-sb) at 12-months compared to placebo.
+++++++++++++++++++++++++
However, consistent with findings in Part A and the Phase 2b trial, lower maximal plasma concentrations of azeliragon in Part B were associated with improvements in efficacy relative to placebo.
“We are eager to obtain early feedback from the FDA based on the results we have achieved and the data that we have observed associating lower plasma levels of the drug and improved efficacy,” said Steve Holcombe, chief executive officer, vTv Therapeutics. “As a result, we believe that azeliragon has the potential to address the pressing unmet need in Alzheimer’s disease.”
While in April and in June 2018 topline results were announced that the A-Study and the B-Study did not meet the co-primary endpoints and clinical trials were ended, subsequent post-hoc subgroup analyses have shown populations that experienced positive benefits.
SO WE ARE WAITING FOR THE RESULTS OF THESE SUB-GROUP
Pyxus International Inc, Inst Holders, 3Q 2018 (PYX)
3:13 am ET October 19, 2018 (Dow Jones) Print
The following table shows the largest shareholders in PYXUS INTERNATIONAL INC COM (PYX) for the quarter ended September 30, 2018, listed by holding size. The list represents up to 50 of the largest holders in the company.
Note: Unless otherwise mentioned the reporting date is 09/30/2018
Institution Shares Shares % Last
Held Changed Held Report
Donald Smith & Co. Inc. 883,488 32,732 8.995 06/30
Dimensional Fund Advisors LP 743,468 (14,679) 7.569 06/30
BlackRock Fund Advisors 499,684 348,519 5.087 06/30
22NW LP 448,426 0 4.566 06/30
The Vanguard Group Inc. 400,424 76,062 4.077 06/30
Aegis Financial Corp. 377,695 (154,624) 3.845 06/30
Pacific Investment Management 362,614 0 3.692 06/30
Renaissance Technologies LLC 269,880 66,700 2.748 06/30
Davenport & Co. LLC 233,312 233,312 2.375 09/30
Connor Clark & Lunn Investmen 166,354 37,450 1.694 06/30
RBF Capital LLC 161,682 (16,500) 1.646 06/30
JPMorgan Securities LLC (Inves 155,376 (24,504) 1.582 06/30
SSgA Funds Management Inc. 119,586 109,273 1.218 06/30
Acadian Asset Management LLC 118,365 12,016 1.205 06/30
William Blair Investment Manag 93,300 0 0.950 06/30
Northern Trust Investments In 92,085 68,716 0.938 06/30
New Jersey Division of Investm 84,000 24,000 0.855 09/30
Algert Global LLC 77,492 5,553 0.789 06/30
Geode Capital Management LLC 71,571 19,133 0.729 06/30
Numeric Investors LLC 70,190 70,190 0.715 06/30
DWS Investment GmbH 65,020 44,992 0.662 06/30
Invesco Advisers Inc. 42,560 (2,570) 0.433 06/30
MacKay Shields LLC 37,600 37,600 0.383 06/30
Oberweis Asset Management Inc 36,300 0 0.370 06/30
Phoenix Investment Adviser LLC 33,241 33,241 0.338 06/30
BlackRock Investment Managemen 28,848 27,380 0.294 06/30
Parametric Portfolio Associate 28,585 28,585 0.291 06/30
Spark Investment Management LL 27,600 27,600 0.281 06/30
Invesco Capital Management LLC 26,731 13,806 0.272 06/30
The Bank of New York Mellon Co 24,611 13,755 0.251 06/30
Alambic Investment Management 19,758 10,708 0.201 06/30
Squarepoint OPS LLC 19,061 19,061 0.194 06/30
Charles Schwab Investment Mana 18,060 18,060 0.184 09/30
Morgan Stanley & Co. LLC 17,826 4,437 0.181 06/30
Auxier Asset Management LLC 16,260 (155) 0.166 06/30
Marshall Wace North America LP 16,087 16,087 0.164 06/30
AQR Capital Management LLC 14,329 14,329 0.146 06/30
Citadel Advisors LLC 13,470 13,470 0.137 06/30
O'Shaughnessy Asset Management 13,384 10,054 0.136 06/30
TIAA-CREF Investment Managemen 12,870 12,870 0.131 06/30
Teachers Advisors LLC 12,856 12,856 0.131 06/30
New York State Common Retireme 9,300 9,300 0.095 06/30
Salem Investment Counselors I 8,017 0 0.082 06/30
Vanguard Fiduciary Trust Co. 7,522 5,792 0.077 06/30
BlackRock Financial Management 7,466 7,466 0.076 06/30
BNY Mellon Asset Management No 6,956 5,599 0.071 06/30
RBC Global Asset Management (U 6,490 0 0.066 06/30
BlackRock Advisors LLC 6,390 6,390 0.065 06/30
PNC Bank NA (Investment Manag 6,050 0 0.062 06/30
UBS Financial Services Inc. 5,735 1,627 0.058 06/30
13F data provided by: Factset Research Systems Inc.;
Please send questions to ownership@factset.com.
Copyright, Factset Research Systems, 2018. All Rights Reserved.
(END) Dow Jones Newswires
October 19, 2018 03:13 ET (07:13 GMT)
i asked before if PYX will venture into CBD drinks
at this time, IMO, they just have e-iquids, vape/hemp oils
then this....
The Company's Global Specialty Products division, which includes the Company's investments in the e-liquids, industrial hemp and legal cannabis space, will continue to be led by Bryan Mazur. In this role, Mazur will oversee the new business lines, which will have requisite autonomy to drive innovation and continue to disrupt these fast-growing categories and diverse consumer markets.
who is/was Bryan Mazur
Alliance One International, Inc. (NYSE: AOI) today announced that Bryan Mazur has joined the Company as Executive Vice President, Global Specialty Products. In this new role, Mr. Mazur will be responsible for global business development and driving innovation and growth. Prior to joining AOI, Mr. Mazur served as Vice President and General Manager of Dr. Pepper Snapple Group, where he built and scaled multiple consumer-facing product brands over the course of 20 years.
then this article..
Keurig Dr. Pepper
Although absolutely no rumors have swirled around Keurig Dr. Pepper (NYSE:KDP), which was formed earlier this year from the merger of Dr. Pepper Snapple Group and Keurig Green Mountain, the maker of single-serve K-cups, I believe it could be the perfect beverage maker to turn to the green rush.
The merger of these two companies is expected to result in cost synergies and improve branding power (and thus pricing power) by giving it more shelf-space clout. But Keurig Dr. Pepper's second-quarter operating results weren't all that impressive. Keurig's sales were essentially flat, while Dr. Pepper Snapple Group saw operating income fall 3.5% as a result of ongoing inflationary pressures. Like Diageo and Coca-Cola, its business needs a spark.
What would make a pairing between Keurig Dr. Pepper and a cannabis company so unique is the company's lead position in the single-serving K-cup space. Even with a number of smaller single-serve, cannabis-focused pod companies popping up in recent years, Keurig would be able to use its deeper pockets and brand name to essentially wipe them off the map.
Secondarily, Keurig Dr. Pepper could also turn to pairing CBD with its well-known sparkling beverage lineup of 7UP, A&W Root Beer, and, of course, Dr. Pepper.
It's certainly not the first name that jumps off the list of big-name beverage companies looking for a cannabis partner, but it may wind up being the most logical.
So, can CBD drinks by PYX possible
Liquidity and Capital Resources
As of March 31, 2018, available credit lines and cash were $625.1 million, comprised of $264.7 million in cash and $360.4 million of credit lines that excluded $7.5 million exclusively for letters of credit. Available credit lines were comprised of $60.0 million under the U.S. ABL credit facility for general corporate purposes and subject to a limitation based on outstanding cash, as well as $300.4 million of foreign seasonal credit lines. In the future, the Company may elect to redeem, repay, make open market purchases, retire, or cancel indebtedness prior to stated maturity under its various global bank facilities and outstanding public notes, as they may permit.
https://www.humblejuiceco.com/
Can CBD drinks be far behind